Education
About Us
Working with TipRanks
Follow Us
Revelation Biosciences (REVB)
NASDAQ:REVB
REVB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.36 - $60.80
Previous CloseN/A
Volume326.26K
Average Volume (3M)177.23K
Market Cap
$3.15M
Enterprise Value-$4.26M
Total Cash (Recent Filing)$6.50M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.47
Next Earnings
May 19, 2025EPS Estimate
-6.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-139.82
Shares Outstanding905,228
10 Day Avg. Volume236,201
30 Day Avg. Volume177,231
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.54
Forecast
1Y Price Target
$20.00Price Target Upside474.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Ownership Overview
5.10% Insiders
1.21% Mutual Funds
0.51% Other Institutional Investors
93.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
REVB FAQ
What was Revelation Biosciences’s price range in the past 12 months?
Revelation Biosciences lowest stock price was $2.36 and its highest was $60.80 in the past 12 months.
What is Revelation Biosciences’s market cap?
Revelation Biosciences’s market cap is $3.15M.
When is Revelation Biosciences’s upcoming earnings report date?
Revelation Biosciences’s upcoming earnings report date is May 19, 2025 which is in 33 days.
How were Revelation Biosciences’s earnings last quarter?
Revelation Biosciences released its earnings results on Mar 06, 2025. The company reported -$4.98 earnings per share for the quarter, beating the consensus estimate of -$10.32 by $5.34.
Is Revelation Biosciences overvalued?
According to Wall Street analysts Revelation Biosciences’s price is currently Undervalued.
Does Revelation Biosciences pay dividends?
Revelation Biosciences does not currently pay dividends.
What is Revelation Biosciences’s EPS estimate?
Revelation Biosciences’s EPS estimate is -6.88.
How many shares outstanding does Revelation Biosciences have?
Revelation Biosciences has 905,228 shares outstanding.
What happened to Revelation Biosciences’s price movement after its last earnings report?
Revelation Biosciences reported an EPS of -$4.98 in its last earnings report, beating expectations of -$10.32. Following the earnings report the stock price went up 0.867%.
Which hedge fund is a major shareholder of Revelation Biosciences?
Currently, no hedge funds are holding shares in REVB
---
Company Description
Revelation Biosciences
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
---
REVB Stock 12 Month Forecast
Average Price Target
$20.00
▲(474.71% Upside)
Technical Analysis
Best Analysts Covering REVB
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-79.20%
reiterated a buy rating last month
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -79.20% per trade.
---